Deterioration in quality of life (QOL) in patients with malignant ascites: Results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 1979-1985

  Wimberger, P ^a   Gilet, H ^b   Gonschior, A K ^c   Heiss, M M ^d   Moehler, M ^e   Oskay Oezcelik, G ^f   Al Batran, S E ^g   Schmalfeldt, B ^h   Schmittel, A ⁱ   Schulze, E ^c   Parsons, S L ^j  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Mapi Consultancy   (France)

^c Fresenius Biotech   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f North Eastern German Society of Gynecological Oncology (NOGGO)   (Germany)

^g KRANKENHAUS NORDWEST   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

Deterioration; Malignant ascites; Quality of life

Indexed keywords

CATUMAXOMAB; EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DETERIORATION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT FOR CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT ASCITES; MULTICENTER STUDY; OPEN STUDY; PARACENTESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 84864924097     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds178     Document Type: Article

References (16)

1. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945-949.
2. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg 1986; 203: 644-651.
3. Feld R. Endpoints in cancer clinical trials: is there a need for measuring quality of life? Support Care Cancer 1995; 3: 23-27.
4. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36: 458-467.
5. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-2221.
6. Hao Y. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert Rev Pharmacoecon Outcomes Res 2010; 10: 407-420.
7. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
8. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353-364.
9. Easson AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. Ann Surg Oncol 2007; 14: 2348-2357.
10. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-144.
11. Scott NW, Fayers PM, Aaronson NK et al. EORTC QLQ-C30 Reference Values. 2008.
12. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42: 589-597.
13. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83: 6-14.
14. Husain A, Bezjak A, Easson A. Malignant ascites symptom cluster in patients referred for paracentesis. Ann Surg Oncol 2010; 17: 461-469.
15. Gonschior AK, Gilet H, Heiss MM et al. Quality of life in patients with malignant ascites and ascites symptoms after treatment with catumaxomab: results from a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Poster presented at European Multidisciplinary Cancer Congress, Stockholm, Sweden. 2011.
16. Schulze E, Parsons SL, Heiss MM, Hennig M. Prolonged ascites symptom-free time in patients with malignant ascites after treatment with catumaxomab. Poster presented at European Multidisciplinary Cancer Congress, Stockholm, Sweden. 2011.